CO vs. VMD, CORBF, QIPT, MRAI, BRTX, MGRX, OTRK, NIVF, FMS, and DVA
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Viemed Healthcare (VMD), Global Cord Blood (CORBF), Quipt Home Medical (QIPT), Marpai (MRAI), BioRestorative Therapies (BRTX), Mangoceuticals (MGRX), Ontrak (OTRK), NewGenIvf Group (NIVF), Fresenius Medical Care (FMS), and DaVita (DVA). These companies are all part of the "miscellaneous health & allied services, not elsewhere classified" industry.
Global Cord Blood vs.
Viemed Healthcare (NASDAQ:VMD) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.
In the previous week, Viemed Healthcare had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 2 mentions for Viemed Healthcare and 1 mentions for Global Cord Blood. Viemed Healthcare's average media sentiment score of 1.67 beat Global Cord Blood's score of 0.59 indicating that Viemed Healthcare is being referred to more favorably in the media.
Viemed Healthcare has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500.
74.2% of Viemed Healthcare shares are held by institutional investors. 20.0% of Viemed Healthcare shares are held by company insiders. Comparatively, 0.5% of Global Cord Blood shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Global Cord Blood received 384 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 76.79% of users gave Global Cord Blood an outperform vote while only 42.86% of users gave Viemed Healthcare an outperform vote.
Global Cord Blood has higher revenue and earnings than Viemed Healthcare. Global Cord Blood is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.
Viemed Healthcare has a net margin of 4.87% compared to Global Cord Blood's net margin of 0.00%. Viemed Healthcare's return on equity of 8.72% beat Global Cord Blood's return on equity.
Summary
Viemed Healthcare beats Global Cord Blood on 10 of the 15 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Global Cord Blood Competitors List
Related Companies and Tools
This page (NYSE:CO) was last updated on 5/23/2025 by MarketBeat.com Staff
